Clinicopathological and prognostic significance of platelet-to-lymphocyte ratio in patients with hepatocellular carcinoma
Metrics: PDF 1534 views | HTML 1800 views | ?
Wei Song1,*, Kai Wang1,*, Fu-ping Zhong1, You-wen Fan1, Lang Peng1, Shu-bing Zou1
1Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China
*These authors have contributed equally to this work
Shu-bing Zou, email: [email protected]
Keywords: platelet to lymphocyte ratio (PLR), hepatocellular carcinoma, biomarker, prognosis, meta-analysis
Received: September 07, 2016 Accepted: October 17, 2016 Published: November 09, 2016
The platelet-to-lymphocyte ratio (PLR) is reported to be a prognostic factor in multiple malignancies. The aim of this study was to assess its prognostic value in hepatocellular carcinoma (HCC). We performed comprehensive searches of electronic databases for relevant studies. A total of eleven studies comprising 2,507 patients were included. Elevated PLR was significantly associated with poor overall survival (OS) (HR = 1.78; 95% CI = 1.36-2.34; P < 0.001) and disease-free survival (DFS)/recurrence-free survival (RFS) (HR = 1.82; 95% CI = 1.56-2.13; P < 0.001). The findings from most subgroup analyses were consistent with those from the overall analysis. In addition, a high PLR correlated with tumor size > 3 cm, TNM stage, lymph node metastasis, distant metastasis, and vascular invasion. We therefore conclude that elevated pretreatment PLR may be predicative of a poor prognosis in patients with HCC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.